Cyclo Therapeutics, Inc. (CYTH)
NASDAQ: CYTH · IEX Real-Time Price · USD
1.180
-0.030 (-2.48%)
Jul 22, 2024, 9:50 AM EDT - Market open
Cyclo Therapeutics Employees
Cyclo Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
$140,806
Profits / Employee
-$2,424,160
Market Cap
34.34M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Nutex Health | 800 |
DarioHealth | 294 |
Achilles Therapeutics | 215 |
Exagen | 179 |
Aadi Bioscience | 89 |
IceCure Medical | 77 |
Xilio Therapeutics | 73 |
iCAD, Inc. | 69 |
CYTH News
- 27 days ago - Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 - Business Wire
- 7 weeks ago - Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 - Business Wire
- 2 months ago - Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 4 months ago - Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update - Business Wire
- 4 months ago - Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease - Business Wire
- 6 months ago - Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office - Business Wire
- 7 months ago - Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. - Business Wire
- 7 months ago - Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1 - Business Wire